Loading...

TCRT ALAUNOS THERAPEUTICS INC US FDA Inspections 8-K Filing

LNS

TCRT

ALAUNOS THERAPEUTICS INC

(TCRT)

2026 8-K

Preclinical Results Revealed

Preclinical Data Announcement

Delisting Notice

Positive Drug Data

Termination Notice

Settlement Agreement

Compliance Regained

Increase in authorized shares

Departures and Appointments

Equity Offerings

Equity Offerings

Equity Offerings

Director Resignation

Board Compensation

License Termination

Reverse Stock Split

Reverse Stock Split

Reverse Stock Split

Reverse Stock Split

Dismissal of Independent Re...

Annual Meeting Approval

Management Changes

Compliance regained with Na...

Reverse Stock Split

Reverse Stock Split

Appointment of Interim CEO

Appointment of Director and...

Management Changes

Resignation of Director

Management Departure

Financial Condition and Del...

Resignation and Appointment

Financial Results and Strat...

Voluntary Delisting

Annual Meeting Approval

Financial Results Announcement

License Agreement Amendment

Loan Agreement Amendment

Management Changes

Earnings Reports

Presentation and Press Release

External Links:

On May 18, 2026, Alaunos Therapeutics, Inc. announced updated preclinical data from studies on ALN1003, an experimental treatment for obesity, emphasizing that the findings are not based on human trials.

AI Assistant

ALAUNOS THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.